ECSP077180A - Compuestos, composiciones y métodos - Google Patents

Compuestos, composiciones y métodos

Info

Publication number
ECSP077180A
ECSP077180A EC2007007180A ECSP077180A ECSP077180A EC SP077180 A ECSP077180 A EC SP077180A EC 2007007180 A EC2007007180 A EC 2007007180A EC SP077180 A ECSP077180 A EC SP077180A EC SP077180 A ECSP077180 A EC SP077180A
Authority
EC
Ecuador
Prior art keywords
compositions
compounds
methods
heart failure
cardiac
Prior art date
Application number
EC2007007180A
Other languages
English (en)
Inventor
Bradley Paul Morgan
Alex Muci
Pu-Ping Lu
Eria Kraynack
Todd Tochimoto
David Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35785669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077180(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of ECSP077180A publication Critical patent/ECSP077180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Ciertos derivados de urea sustituidos modulan selectivamente el sarcómero cardiaco, por ejemplo potenciando la miosina cardiaca, y son útiles en el tratamiento de la insuficiencia cardiaca sistólica, incluyendo la insuficiencia cardiaca congestiva
EC2007007180A 2004-06-17 2007-01-17 Compuestos, composiciones y métodos ECSP077180A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58119704P 2004-06-17 2004-06-17

Publications (1)

Publication Number Publication Date
ECSP077180A true ECSP077180A (es) 2007-04-26

Family

ID=35785669

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007180A ECSP077180A (es) 2004-06-17 2007-01-17 Compuestos, composiciones y métodos

Country Status (33)

Country Link
US (12) US7507735B2 (es)
EP (2) EP2862859B1 (es)
JP (2) JP5080970B2 (es)
KR (1) KR101276136B1 (es)
CN (1) CN101035525A (es)
AR (1) AR053405A1 (es)
AU (1) AU2005264988B2 (es)
BR (1) BRPI0512193B8 (es)
CA (1) CA2570999C (es)
CY (1) CY1115716T1 (es)
DK (2) DK2862859T3 (es)
EA (1) EA016138B1 (es)
EC (1) ECSP077180A (es)
ES (2) ES2522579T3 (es)
HK (2) HK1101060A1 (es)
HR (1) HRP20141048T1 (es)
IL (1) IL180026A (es)
MA (1) MA28738B1 (es)
ME (1) ME01942B (es)
MX (1) MXPA06014495A (es)
MY (1) MY144470A (es)
NO (1) NO340030B1 (es)
NZ (1) NZ552404A (es)
PE (1) PE20060438A1 (es)
PL (2) PL216049B1 (es)
PT (1) PT1765327E (es)
RS (1) RS53600B1 (es)
RU (1) RU2410384C2 (es)
SG (1) SG149027A1 (es)
SI (1) SI1765327T1 (es)
TW (1) TWI359812B (es)
WO (1) WO2006009726A2 (es)
ZA (1) ZA200700351B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
EP2397462A3 (en) * 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
MY144470A (en) 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1824843A2 (en) * 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP1828169A2 (en) * 2004-12-07 2007-09-05 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2007081690A2 (en) * 2006-01-04 2007-07-19 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2014515839A (ja) 2011-04-20 2014-07-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 最小角度依存性を有する表示装置及びイメージング用のスペクトルフィルタリング
CN102288601B (zh) * 2011-05-16 2012-12-12 中国药科大学 一种肌球蛋白atp酶活性微量测定方法及其应用
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US9709649B2 (en) * 2013-02-08 2017-07-18 Regents Of The University Of Minnesota System and method for assessing adenosine triphosphate hydrolysis rate using double saturation transfer magnetic resonance imaging and spectroscopy
RU2663663C2 (ru) * 2013-03-14 2018-08-08 Эмджен Инк. Соль омекамтива мекарбила и способ ее получения
CA2902424A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
US9547107B2 (en) 2013-03-15 2017-01-17 The Regents Of The University Of Michigan Dye and pigment-free structural colors and angle-insensitive spectrum filters
WO2015142001A2 (ko) * 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
WO2016210240A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
US10538478B2 (en) 2016-10-10 2020-01-21 Basf Se Catalyst modification with alkali metal, alkaline earth metal or rare earth metal ions in the continuous liquid-phase hydrogenation of nitro compounds
US10256925B2 (en) * 2017-01-19 2019-04-09 Samsung Electronics Co., Ltd. Methods and wireless communication systems for wireless re-calibration of RF components of communication devices
RS62328B1 (sr) * 2017-06-30 2021-10-29 Amgen Inc Sinteza omekamtiv mekarbila
CA3068588A1 (en) 2017-06-30 2019-01-03 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
JP7401439B2 (ja) * 2018-01-19 2023-12-19 サイトキネティックス， インコーポレイテッド 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020047447A1 (en) 2018-08-31 2020-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) * 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
AU2021380754A1 (en) 2020-11-12 2023-06-22 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2022192414A2 (en) 2021-03-10 2022-09-15 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397782A (en) * 1889-02-12 Plunger water-closet
NL254871A (es) 1959-08-14
US3939169A (en) * 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2942930A1 (de) 1979-10-24 1981-05-27 Basf Ag, 6700 Ludwigshafen Substituierte harnstoffe, deren herstellung und verwendung als herbizide
DE3147879A1 (de) 1981-12-03 1983-06-16 Basf Ag, 6700 Ludwigshafen 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
CA1185974A (en) 1981-12-03 1985-04-23 Adolf Parg 1,3,5-triazinones and their use for controlling undesirable plant growth
AU2818584A (en) 1983-03-29 1984-10-25 Fmc Corporation N-phenyl-n-(pyridinyl-n-oxide)urea plant regulators
US4787931A (en) 1984-03-06 1988-11-29 Fmc Corporation N-phenyl-N'-(pyridinyl-N-oxide)urea plant regulators
US4672066A (en) * 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GEP20001968B (en) 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
RU94046149A (ru) * 1992-05-28 1996-11-27 Пфайзер Инк. (US) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
JP3697486B2 (ja) * 1994-10-27 2005-09-21 アステラス製薬株式会社 ブラジキニン拮抗剤としての、ピリドピリミドン類、キノリン類および縮合ｎ−複素環類
US6010026A (en) 1994-11-22 2000-01-04 Aluminum Company Of America Assembly of aluminum can and threaded sleeve
US5556969A (en) * 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
ES2186907T3 (es) * 1996-07-23 2003-05-16 Neurogen Corp Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1.
IT1284198B1 (it) 1996-07-30 1998-05-08 Beniamino Anzalone Carne vegetale
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO390996A0 (en) 1996-11-29 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998041510A1 (fr) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
WO1998052559A1 (en) 1997-05-23 1998-11-26 Bayer Corporation Raf kinase inhibitors
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Ag Hemmung von p38 kinase aktivität durch arylharnstoff
WO1999023090A1 (en) * 1997-11-05 1999-05-14 Choongwae Pharma Corporation Novel genipin derivative having liver protection activity
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
JP4403482B2 (ja) 1997-12-22 2010-01-27 バイエル コーポレイション 置換複素環尿素合成のための中間体およびその製造方法
EP1042305B1 (en) 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
RU2247109C9 (ru) 1997-12-22 2005-06-20 Байер Копэрейшн Симметричные и несимметричные производные дифенилмочевины (варианты), фармацевтическая композиция, способ подавления роста опухолевых клеток, опосредованного киназой raf
CZ299156B6 (cs) 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
EP1086078B1 (en) 1998-06-08 2003-02-05 Schering Corporation Neuropeptide y5 receptor antagonists
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
JP3594317B2 (ja) * 1998-08-11 2004-11-24 住友製薬株式会社 ナフチリジン誘導体
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000052004A1 (en) * 1999-03-01 2000-09-08 The Regents Of The University Of California Thiacrown polymers for removal of mercury from waste streams
DE19921498A1 (de) * 1999-05-08 2000-11-16 Clariant Gmbh Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen
MXPA02000314A (es) * 1999-07-09 2004-06-22 Boehringer Ingelheim Pharma Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
WO2001007411A1 (fr) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
JP4955171B2 (ja) 1999-11-16 2012-06-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
AU2001271357A1 (en) 2000-06-21 2002-01-02 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0015904D0 (en) 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
US6573267B2 (en) * 2000-06-30 2003-06-03 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
WO2002006231A1 (fr) 2000-07-18 2002-01-24 Sumitomo Pharmaceuticals Co., Ltd. Inhibiteurs de recaptage de la serotonine
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
JP2002220338A (ja) 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
GB0117950D0 (en) * 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
ATE355272T1 (de) 2001-04-20 2006-03-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
MXPA03010487A (es) 2001-05-16 2004-03-09 Boehringer Ingelheim Pharma Derivados de diarilurea utiles como agentes antiinflamatorios.
EP1395561A1 (en) * 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
AU2002346048A1 (en) 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
AU2002316459A1 (en) * 2001-07-11 2003-01-29 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
EP1426360A4 (en) 2001-09-12 2006-04-12 Kaken Pharma Co Ltd 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICAMENTS CONTAINING THE SAME
US7320126B2 (en) * 2001-11-06 2008-01-15 Sandisk Corporation Implementation of in system programming to update firmware on memory cards
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
CA2470427C (en) 2001-12-21 2012-07-10 Cytokinetics, Incorporated Compositions and methods for treating heart failure
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1472248A1 (en) 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DE10208986A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
JP4471262B2 (ja) 2002-03-07 2010-06-02 株式会社エス・ディー・エス バイオテック 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤
JP4602672B2 (ja) 2002-03-28 2010-12-22 メルク セローノ ソシエテ アノニム プロスタグランジンｆ受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
WO2003082808A1 (fr) 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Company, Limited. Derives de benzamide
DK1499316T3 (da) 2002-04-18 2008-07-21 Schering Corp (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US20060052600A1 (en) 2002-05-17 2006-03-09 Nielsen Simone F Amino-functional chalcones
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
DK1539742T3 (da) 2002-06-24 2006-12-27 Schering Corp Indolderivater, der er nyttige som histamin H3-antagonister
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
KR20050026535A (ko) 2002-07-31 2005-03-15 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3 억제성 안트라닐아미도피리딘
GB0218147D0 (en) 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
AU2003262262A1 (en) 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
KR101088922B1 (ko) 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
US6915814B2 (en) * 2002-09-04 2005-07-12 Dara Cheng Transparent pipe trap with means of enhancing the biodegradation of sink effluents
BR0314201A (pt) 2002-09-10 2005-07-12 Pfizer Prod Inc Compostos diazabicìclicos úteis no tratamento de doenças do cns e outros distúrbios
EP1558203B1 (fr) 2002-10-29 2007-05-09 L'oreal Composition capillaire contenant un compose styryl-pyrazole
EP2397462A3 (en) * 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AU2003902073A0 (en) * 2003-05-01 2003-05-15 Kevin Raymond Deguara A lighting substrate
DE602004026289D1 (de) * 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
US20070010529A1 (en) 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
US8796250B2 (en) * 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
WO2005051366A2 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
ES2505090T3 (es) 2004-05-07 2014-10-09 Amgen Inc. Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer
MY144470A (en) 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
WO2006009729A2 (en) 2004-06-18 2006-01-26 Medtronic, Inc. Methods and devices for occlusion of an atrial appendage
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
US7672247B2 (en) * 2006-02-23 2010-03-02 International Business Machines Corporation Evaluating data processing system health using an I/O device

Also Published As

Publication number Publication date
US20140038983A1 (en) 2014-02-06
US20220185779A1 (en) 2022-06-16
CY1115716T1 (el) 2017-01-25
US10035770B2 (en) 2018-07-31
US8110595B2 (en) 2012-02-07
US7507735B2 (en) 2009-03-24
SI1765327T1 (sl) 2014-12-31
US20090036447A1 (en) 2009-02-05
PL1765327T3 (pl) 2015-01-30
US20090099198A1 (en) 2009-04-16
US20190352267A1 (en) 2019-11-21
EP2862859A3 (en) 2015-05-06
ES2522579T3 (es) 2014-11-17
IL180026A (en) 2011-11-30
NZ552404A (en) 2010-04-30
EP1765327A2 (en) 2007-03-28
BRPI0512193B1 (pt) 2018-11-21
EP1765327A4 (en) 2009-06-17
NO340030B1 (no) 2017-02-27
WO2006009726A2 (en) 2006-01-26
BRPI0512193B8 (pt) 2021-05-25
PT1765327E (pt) 2014-11-24
MA28738B1 (fr) 2007-07-02
PE20060438A1 (es) 2006-07-01
ES2686357T3 (es) 2018-10-17
HK1209729A1 (en) 2016-04-08
RS53600B1 (en) 2015-02-27
US8513257B2 (en) 2013-08-20
CN101035525A (zh) 2007-09-12
US20120172372A1 (en) 2012-07-05
KR20070046070A (ko) 2007-05-02
NO20070257L (no) 2007-01-16
PL381801A1 (pl) 2007-07-09
US10385023B2 (en) 2019-08-20
EA200700058A1 (ru) 2007-08-31
US8101617B2 (en) 2012-01-24
AU2005264988B2 (en) 2011-09-22
AR053405A1 (es) 2007-05-09
TWI359812B (en) 2012-03-11
KR101276136B1 (ko) 2013-06-18
ME01942B (me) 2015-05-20
US20150005296A1 (en) 2015-01-01
CA2570999C (en) 2014-01-07
DK1765327T3 (da) 2014-11-03
US9643925B2 (en) 2017-05-09
BRPI0512193A (pt) 2008-02-19
JP2008503467A (ja) 2008-02-07
EP2862859B1 (en) 2018-07-25
US20180305316A1 (en) 2018-10-25
HK1101060A1 (en) 2007-10-05
RU2410384C2 (ru) 2011-01-27
JP5080970B2 (ja) 2012-11-21
IL180026A0 (en) 2007-05-15
WO2006009726A3 (en) 2006-11-30
PL216049B1 (pl) 2014-02-28
SG149027A1 (en) 2009-01-29
ZA200700351B (en) 2008-05-28
CA2570999A1 (en) 2006-01-26
US20210198203A1 (en) 2021-07-01
US10975034B2 (en) 2021-04-13
AU2005264988A1 (en) 2006-01-26
HRP20141048T1 (hr) 2015-01-02
US9150564B2 (en) 2015-10-06
RU2007101619A (ru) 2008-08-10
EP1765327B1 (en) 2014-08-13
EP2862859A2 (en) 2015-04-22
MXPA06014495A (es) 2007-03-01
US20060014761A1 (en) 2006-01-19
TW200616996A (en) 2006-06-01
EA016138B1 (ru) 2012-02-28
DK2862859T3 (en) 2018-08-13
US20170267638A1 (en) 2017-09-21
US20160115133A1 (en) 2016-04-28
US8871769B2 (en) 2014-10-28
JP2012097093A (ja) 2012-05-24
MY144470A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
ECSP077180A (es) Compuestos, composiciones y métodos
MXPA05007513A (es) Compuestos, composiciones y metodos.
EP1605752A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
WO2007089336A3 (en) Certain chemical entities, compositions and methods
WO2007078839A3 (en) Compounds, compositions and methods
WO2007070683A3 (en) Certain chemical entities, compositions and methods
WO2007070626A3 (en) Certain chemical entities, compositions and methods
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA200801406A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
NO20065178L (no) Tienopyridinderivater
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
ATE510822T1 (de) Kaliumkanalinhibitoren
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
WO2003059258A3 (en) Compositions and methods for treating heart failure
EA200701852A1 (ru) Производные аминокислот
WO2003059265A3 (en) Compositions and methods for treating heart failure
BRPI0510407A (pt) derivados de 3-amino-2-fenilpirrolidina